Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maxygen Inc.

www.maxygen.com

Latest From Theravance Biopharma Inc.

Are Theravance And Mylan's US COPD Chances Bigger Than First Thought?

With Theravance Biopharma's promising once-daily nebulized LAMA bronchodilator, partnered with Mylan, set for FDA filing later this year, analysts say the product might have a bigger market than initially presumed, and are now looking beyond to the firm's other pipeline activities.

Clinical Trials Respiratory

Pipeline Watch: Phase III Starts For Itacitinib And AXS-05

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

HCV Patient Access: Trek Therapeutics Takes The Road Less Traveled

Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.

BioPharmaceutical Infectious Diseases

Pipeline Watch: Top-Line Ozanimod, Romosozumab, Cariprazine Phase III Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Maxygen Inc.
  • Senior Management
  • James Sulat, CEO
    Lawrence Briscoe , SVP, CFO
    Elliot Goldstein, MD, COO & CMO
  • Contact Info
  • Maxygen Inc.
    Phone: (650) 298-5300
    301 Galveston Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register